Drug intelligence / Profile preview

China Medical Univ. XO compound g25

Development stage: Unknown
Lead developer: China Medical University

Overview

China Medical Univ. XO compound g25: sourced facts only. name: "Enzyme kinetic studies revealed that compound g25 acted as a mixed-type XO inhibitor." [PMID:35752100]; target: "Enzyme kinetic studies revealed that compound g25 acted as a mixed-type XO inhibitor." [PMID:35752100]; developer: "School of Pharmacy, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China." [PMID:35752100]; stage: "In addition, in vivo activity evaluation demonstrated that compound g25 exhibited obviously hypouricemic effect on a potassium oxonate induced hyperuricemic rat model." [PMID:35752100]

Beyond the preview

Go deeper on China Medical Univ. XO compound g25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Medical Univ. XO compound g25.